Interferon News and Research

RSS

Researchers identify key gene that may be a marker of breast cancer metastasis

Despite the fact that they both infect the liver, the hepatitis A and hepatitis C viruses actually have very little in common.

19 Apr 2007

Researchers find hepatitis A and hepatitis C attack same protein to block immune defenses

Despite the fact that they both infect the liver, the hepatitis A and hepatitis C viruses actually have very little in common.

19 Apr 2007

Anadys Pharmaceuticals presents data showing ANA773 promotes anti-tumor activity of killer cells

Anadys Pharmaceuticals presented data from an in vitro study showing that the active metabolite of ANA773 promotes natural killer (NK) cell-mediated anti-tumor response by inducing cytokine secretion, cytolysis of tumor cells and enhanced antibody-dependent cellular cytotoxicity (ADCC), during a poster presentation at the Annual Meeting of the American Association of Cancer Research (AACR) in Los Angeles.

18 Apr 2007

MS patients not receiving medications to slow disease progression

Neurologists at Wake Forest University Baptist Medical Center have found that many patients diagnosed with multiple sclerosis (MS) are not taking or being prescribed drugs approved to treat the disease.

17 Apr 2007

Expression Genetics completes phase I trial of lead drug candidate, EGEN-001

Expression Genetics, Inc., has announced the completion of a Phase I clinical study evaluating the Company's lead drug candidate, EGEN-001.

17 Apr 2007

Human Genome Sciences reports results of phase 2b trial of Albuferon

Human Genome Sciences has reported results at Week 12 following the completion of therapy (SVR12) in a Phase 2b clinical trial of Albuferon(R) (albinterferon alfa-2b) in combination with ribavirin in patients with genotype 1 chronic hepatitis C who are naive to interferon alpha-based treatment regimens.

16 Apr 2007

New drug therapy zaps hepatitis C in 12 weeks

Trials of new hepatitis C drug suggest sufferers could be cleared of the virus within 12 weeks of treatment.

16 Apr 2007

Intarcia Therapeutics announces results from study of injectable Omega Interferon plus Ribavirin for treatment of hepatitis C genotype-1

Intarcia Therapeutics has announced final results from a Phase 2 study of omega interferon with or without ribavirin in treatment-naive patients with genotype 1 chronic hepatitis C.

15 Apr 2007

GlaxoSmithKline initiates study of PROMACTA in chronic idiopathic thrombocytopenic purpura

GlaxoSmithKline has announced the initiation of a global, open-label, single group trial that will assess the efficacy, safety and tolerability of PROMACTA (eltrombopag olamine) in patients previously treated for chronic idiopathic thrombocytopenic purpura (ITP).

15 Apr 2007

India is poised to revolutionize biotechnology

India's health biotech firms are emerging as a major global player, with growing means and know-how to produce innovative as well as generic drugs and vaccines at costs small relative to those of giant Western firms, according to ground-breaking Canadian research.

10 Apr 2007

Researchers show blood-brain barrier damage could affect multiple sclerosis severity

Immunology researchers at the Kimmel Cancer Center at Jefferson studying a multiple sclerosis (MS)-like disease in mice have shown that the amount of "damage" to the central nervous system's protective blood-brain barrier, in essence, opening it, almost always correlates to the severity of the disease.

7 Apr 2007

Body uses a 'dual key' system to secure immune system

"Dual key" activation, in which two people must act in concert to launch a weapon, is often installed to safeguard highly destructive arms.

2 Apr 2007

Interferon gamma identified as one of the signaling proteins involved with tumor relapse

Researchers at Virginia Commonwealth University's Massey Cancer Center studying the interaction between the immune system and cancer cells have identified interferon gamma as one of the signaling proteins involved with tumor relapse.

13 Mar 2007

Chemoimmunotherapy versus chemotherapy for metastatic malignant melanoma

The addition of immunotherapy to chemotherapy for malignant skin cancer that has spread does not improve survival rates, researchers have found, and patients have more serious side effects, such as anemia, when the two treatments are combined.

1 Mar 2007

Sunitinib halts progress of metastatic kidney cancer

Research has shown the efficacy of a pharmaceutical drug known as sunitinib which halts progress of metastatic kidney cancer.

1 Mar 2007

Antipodean Pharma commences phase 2 trial in hepatitis C

Antipodean Pharmaceuticals has announced it has initiated a Phase 2 clinical trial of its lead compound MitoQ (mitoquinone) to investigate the drug's efficacy to reduce liver damage in patients with raised liver enzymes associated with the Hepatitis C virus (HCV).

5 Feb 2007

Hepatitis C virus replication in transfected and serum-infected cultured human fetal hepatocytes

Researchers open the way for improved study of hepatitis C virus by devising a novel virus culture system that allows replication of patient-isolated virus in nontransformed hepatocytes, instead of culture-adapted virus strains in transformed cell lines.

23 Jan 2007